WEHI-345

• UNSPSC Description:

  WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation[1].

• Target Antigen:

  RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/WEHI-345.html

• Purity:

  99.31

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=NC=C1)NCC(C)(N2N=C(C3=CC=C(C)C=C3)C4=C(N)N=CN=C42)C

• Molecular Weight:

  401.46

• References & Citations:

  [1]Nachbur U, et al. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nat Commun. 2015 Mar 17;6:6442.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1354825-58-3